Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 4/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP24A1 | Q07973 | 5/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10857936 | 0.80 | CYP19A1 (0.50) | CYP17A1CYP19A1KDM4ECYP24A1CYP26A1 | |
| SCHEMBL10862203 | 0.80 | CYP19A1 (0.50) | CYP17A1CYP19A1KDM4ECYP24A1CYP26A1 | |
| SCHEMBL6898202 | 0.79 | CYP17A1 (0.44) | CYP17A1CYP19A1KDM4ETBXAS1CYP26A1 | |
| SCHEMBL9706448 | 0.78 | KDM4E (0.55) | CYP17A1CYP19A1KDM4ECYP26A1 | |
| SCHEMBL7241225 | 0.78 | TBXA2R (0.54) | CYP17A1CYP19A1KDM4ECYP24A1CYP26A1 | |
| SCHEMBL10612567 | 0.78 | CYP19A1 (0.49) | CYP17A1CYP19A1KDM4ECYP24A1CYP26A1 | |
| Bromide SCHEMBL11032120 | 0.78 | CYP19A1 (0.49) | CYP17A1CYP19A1KDM4ECYP24A1CYP26A1 | |
| Hydrochloric Acid SCHEMBL28870357 | 0.77 | CYP17A1 (0.43) | CYP17A1CYP19A1KDM4ETBXAS1CYP26A1 | |
| Bromide SCHEMBL28405764 | 0.77 | CYP17A1 (0.43) | CYP17A1CYP19A1KDM4ETBXAS1CYP26A1 | |
| Hydrochloric Acid SCHEMBL412293 | 0.77 | TBXA2R (0.53) | CYP17A1CYP19A1KDM4ECYP24A1CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879873-B1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-10-09 | — | — | EP | disclosed |
| US-7598279-B2 | Neurotherapeutic azole compounds | SK HOLDINGS CO., LTD. (KR) | 2009-10-06 | — | — | US | disclosed |
| EP-1879873-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-20060258718-A1 | Neurotherapeutic azole compounds | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2006-11-16 | — | — | US | disclosed |
| WO-2006112685-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2006-10-26 | — | — | WO | disclosed |
| EP-0131302-B1 | IMIDAZOLIUM SALTS, INTERMEDIATES THERETO AND THEIR USE | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258718-A1 | Neurotherapeutic azole compounds | CHRNA10, CHRNA4, CHRNA3 | CYP17A1 551/4885CYP19A1 434/4885KDM4E 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.